The Newborn Drug Development Initiative

Pediatrics

Volumn 117, Issue 3, 2006, Pages

  Giacoia, George P ^a   Birenbaum, Debra L ^b   Sachs, Hari Cheryl ^b   Mattison, Donald R ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical research trials; Clinical trial design; Neonatology

Indexed keywords

NITRIC OXIDE; SURFACTANT;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LAW; LOW BIRTH WEIGHT; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICAL RESEARCH; META ANALYSIS; NEWBORN INTENSIVE CARE; PREMATURITY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; DRUG LEGISLATION; DRUG SCREENING; DRUG THERAPY; ETHICS; HEALTH CARE ORGANIZATION; LEGAL ASPECT; NEWBORN; NEWBORN DISEASE; UNITED STATES;

BIOMEDICAL RESEARCH; CLINICAL TRIALS; DRUG EVALUATION; DRUG THERAPY; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LEGISLATION, DRUG; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33745525992     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-0620B     Document Type: Conference Paper

References (39)

1. Villar J, Abalos E, Carroli G, et al. Heterogeneity of perinatal outcomes in the preterm delivery syndrome. Obstet Gynecol. 2004;104:78-87
2. Barr J, Brenner-Zada G, Heiman E, et al. Unlicensed and offlabel medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002;19:67-72
3. O'Donnell C, Stone R, Morley C. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002;110(5). Available at: www.pediatrics.org/cgi/content/full/110/5/e52
4. McIntyre J, Choonara I. Drug toxicity in the neonate. Biol Neonate. 2004;86:218-221
5. Euler A, Byrne L, Cousins M, Ament E, Walsh J. Increased serum gastrin concentrations and gastric acid hyposecretion in the immediate newborn period. Gastroenterology. 1977;72:1271-1273
6. Berseth C. Gestational evolution of small intestine motility in preterm and term infants. J Pediatr. 1989;115:646-651
7. Boehm G, Braun W, Moto G, Minoli I. Bile acid concentrations in serum and duodenal aspirates of healthy preterm infants: effects of gestational and postnatal age. Biol Neonate. 1997;71:207-214
8. Barret D, Rutter N. Transdermal delivery and the premature neonate. Crit Rev Ther Drug Carrier Syst. 1994;11:1-30
9. Radde IC. Mechanisms of drug absorption and their development. In: McLeod SM, Radde IC, eds. Textbook of Pediatric Clinical Pharmacology. Littleton, MA: PSG Publishing; 1985:17-43
10. McNamara P, Alcorn J. Protein binding predictions in infants. AAPS PharmSci. 2002;4:E4
11. Pacifi GM, Viani A, Taddeucci-Brunelli G, Rizzo G, Carrai M, Schltz HU. Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and alpha 1-acid glycoprotein: implications for binding of drugs. Ther Drug Monit. 1986;8:259-263
12. Ellis KJ, Shypailo RJ, Shandler RJ. Body composition of the preterm infant. Ann Hum Biol. 1994;21:533-545
13. Hartnoll G, Betremieux P, Modi N. Body water content of extremely preterm infants at birth. Arch Dis Child Fetal Neonatal Ed. 2000;83:F56-F59
14. Kluckow M, Evans N. Low systemic blood flow in the preterm infant. Semin Neonatol. 2001;6:75-84
15. Williams BS, Ransom JL, Gal P, Carlos RQ, Smith M, Schall SA. Gentamicin pharmacokinetics in neonates with patent ductus arteriosus. Crit Care Med. 1997;25:273-275
16. Bueva A, Guignard J. Renal function in preterm infants. Pediatr Res. 1994;36:572-577
17. Van den Anker X. Pharmacokinetics and renal function in preterm infants. Acta Paediatr. 1996;85:1393-1399
18. Jones D, Chesney R. Development of tubular function. Clin Perinatol. 1992;19:33-57
19. Horn L, Kuhn R, Kanga J. Evaluation of the reproducibility of tablet splitting to provide accurate doses for the pediatric population. J Pediatr Pharm Pract. 1999;4:38-42
20. Edwards W, Goldmann D, Gray J, et al. Voluntary anonymous reporting of medical errors for neonatal intensive care. Pediatrics. 2004;113:1609-1618
21. Nahata M, Hipple T. Pediatric Drug Formulations. Cincinnati, OH: Harvey Whitney; 2000
22. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C. Incidence of adverse drug reactions in paediatric in/out patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52:77-83
23. Aranda J, Portuguez-Malavasi A, Collinge J, et al. Epidemiology of adverse drug reactions in the newborn. Dev Pharmacol Ther. 1982;5:173-184
24. Knight M. Adverse drug reactions in neonates. J Clin Pharmacol. 1994;34:128-355
25. Blake M, Castro L, Leeder J, Kearns G. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med. 2005;10:123-138
26. Hines R, McCarver D. The ontogeny of human drugmetabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther. 2002;300:355-360
27. Mc Carver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther. 2002;300:361-366
28. Glasgow X, Boeck R, Miller M, MacDonald M, August G, Goodman S. Hyperosmolality in small infants due to propylene glycol. Pediatrics. 1983;72:353-355
29. Gershanik J, Boecler B, Ensley H, McClosky S, George W. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982;307:1384-1388
30. Kumar P. Issues in the formulation of drugs for oral use in children: role of excipients. Paediatr Drugs. 2002;4:371-379
31. Carleton B, Lesko A, Milton J, Poole R. Active surveillance systems for pediatric adverse drug reactions: an idea whose time has come. Curr Ther Res. 2001;62:738-742
32. Jevtovic-Todorovic V, Hartman R, Isumi Y, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci. 2003;23:876-882
33. Anand K, Soriano S. Anesthetic agents and the immature brain: are these toxic or therapeutic agents? Anesthesiology. 2004;101:527-530
34. Abdel-Rahman, Kauffman R. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu Rev Pharmacol Toxicol. 2004;44:111-136
35. Field MJ, Behrman RE, eds. Ethical Conduct of Clinical Research Involving Children. Washington, DC: Committee on Clinical Research Involving Children, Board on Health Science Policy, Institute of Medicine of the National Academies; 2004
36. Ackerman T. The ethics of drug research in children. Paediatr Drugs. 2001;3:29-41
37. Kannan S, Raykoua M, Glibetec M, Kannan RM, Lieh-Lai M, Basset D. Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J Biomater Sci Polym Ed. 2004;15:311-330
38. Kolhe P, Khandare J, Pillai O, Kannan S, Lieh-Lai M, Kannan R. Hyperbranched polymer-drug conjugates with high drug payload for enhanced cellular delivery. Pharm Res. 2004;21:2185-2195
39. Chan FK, Chew NY. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev. 2003;55:793-805